Introduction
Congenital thrombotic thrombocytopenic purpura, commonly called cTTP, is a rare inherited blood disorder that can cause dangerous blood clot formation throughout the body. The condition occurs when the body has very low or absent activity of an enzyme called ADAMTS13, which normally helps regulate blood clotting processes. Without adequate ADAMTS13 enzyme activity, abnormal clot formation may occur in small blood vessels and lead to serious complications involving the brain, heart, kidneys, and other organs.
People living with cTTP may experience recurring episodes involving low platelet counts, anemia, neurologic symptoms, fatigue, organ damage, and other potentially life-threatening complications. Because cTTP is a lifelong rare disease, ongoing monitoring and preventive treatment are often important parts of long-term disease management.
Adzynma is a recombinant ADAMTS13 enzyme replacement therapy designed to help replace the missing or deficient ADAMTS13 enzyme in people with congenital TTP. The medication may be used both for preventive treatment and for on-demand treatment of acute cTTP episodes in adults and children.
By restoring ADAMTS13 activity, Adzynma helps reduce abnormal blood clot formation and targets the underlying cause of congenital TTP. The medication became the first FDA-approved recombinant ADAMTS13 therapy specifically approved for cTTP treatment.
Although advances in rare disease treatment may improve disease management and long-term outcomes, specialty biologic therapies like Adzynma often mean extremely high treatment costs. Specialty pharmacy coordination, infusion-related care, insurance authorization requirements, and ongoing monitoring may create additional financial and logistical challenges for patients and families.
Prescription Hope helps qualified patients access needed medications through patient assistance programs. Our advocates work on behalf of patients to help simplify enrollment coordination, gather required documentation, and provide ongoing support whenever possible.
Through Prescription Hope’s medication access service, patients and families may receive guidance and assistance while navigating medication affordability concerns associated with high-cost rare disease therapies like Adzynma.
What Is the Adzynma Patient Assistance Program?
When searching for their medication, many Americans must evaluate costs to determine whether they can get the needed meds. For those dealing with Adzynma costs, paying for out-of-pocket expenses can be extremely difficult.
Pharmaceutical manufacturers understand that some of the medications they produce may be too expensive for most Americans. In an effort to help, many manufacturers will launch Patient Assistance Programs.
These programs offer patients, often struggling financially, access to affordable medications.
Those who qualify for the Adzynma Patient Assistance Program can get affordable Adzynma for their cTTP medication assistance.
However, Patient Assistance Programs are notorious for difficult application processes and complex requirements.
Having someone to help navigate the confusing landscape of patient assistance programs can mean the difference between approval and rejection.
How Expert Advocates Help Make Adzynma More Affordable
Professional Application Management
Those who have attempted to apply for a Patient Assistance Program on their own understand the difficulties of applying.
Prescription Hope offers a solution. For $70.00 per month, per medication, patients who qualify not only get a trained patient advocate who handles every stage of their application, but also continuing support for as long as they are a patient with Prescription Hope.
We handle completing forms, collecting all required documents, healthcare provider signatures, and more.
Predictable Monthly Pricing
Thankfully, there are plenty of ways to secure medication affordability. However, each option has its strengths and weaknesses.
While discount cards, insurance programs, coupons, and more offer patients a chance to save, they can leave patients frustrated.
Discount cards and coupons often provide small savings compared to the cost of the medication. Insurance coverage may not be adequate, or deductibles and co-pays are too high to benefit.
Prescription Hope is different. We are not a discount card, insurance program, coupon, or affiliated with any assistance program.
Instead, we are a comprehensive medication access service that helps patients secure affordable medications through patient assistance programs.
For a predictable $70.00 per med, per month, patients who qualify can get affordable Adzynma and rare disease medication support.
That means no hassles, no hidden fees, no strings attached, and no surprises.
And if a patient does not qualify for their medication’s patient assistance program, we’ll work with them to find other savings options, including substitute medications and their programs, or other assistance opportunities.
But if we can’t help, we won’t charge you.
Ongoing Advocacy and Refill Support
After approval, we don’t stop working for you.
Once your first order of medication ships directly from the manufacturer, we continue to handle refill scheduling, document updates, yearly renewals, and account monitoring. We handle the entire process for as long as you’re a patient with us.
Adzynma Patient Assistance Eligibility
Wondering if you’re eligible for the Adzynma Patient Assistance Program? Patients must meet criteria in several areas. Some of those qualification factors include:
Insurance: Each program has its own insurance status requirements.
Income: Every program maintains its own income level qualifications.
Residency: Patients must be valid U.S. residents.
Prescription: To qualify, every applicant must have a valid prescription for the medication being applied for.
Simple Enrollment With Expert Support
Starting Your Journey
Those seeking medication access through the Adzynma Patient Assistance Program may benefit from Prescription Hope’s enrollment support. Our enrollment process only takes 6 steps. Those include:
- Submit Information: Take a few minutes to fill out our enrollment form.
- Advocate Contact: Once you complete the form, an advocate will contact you within 1-2 business days.
- Document Collection: Following prequalification, our team will begin collecting all necessary documentation.
- Provider Coordination: We’ll coordinate with your healthcare provider for needed signatures.
- Program Submission: Once everything is in order, we’ll submit your application and continue to coordinate with the manufacturer.
- Medication Delivery: After approval, patients can typically expect their medication to arrive within 2 weeks, directly to their door or doctor’s office.
Medication Delivery and Ongoing Support
After the first delivery of medication, Prescription Hope will continue to help with medication coordination. Our ongoing support includes document updates, account monitoring, yearly renewals, and more.
We serve patients for as long as they are patients with us. All for $70.00 per month, per medication.
Understanding Adzynma
How Adzynma Works
Adzynma works by replacing the missing or deficient ADAMTS13 enzyme in people with congenital thrombotic thrombocytopenic purpura (cTTP). Under normal conditions, the ADAMTS13 enzyme helps regulate a blood-clotting protein called von Willebrand factor, also known as VWF.
When ADAMTS13 enzyme activity is very low or absent, unusually large VWF structures may build up in the bloodstream and contribute to abnormal blood clot formation in small blood vessels. These small clots can interfere with blood flow and potentially cause damage to organs and tissues throughout the body.
By restoring ADAMTS13 activity, Adzynma helps reduce abnormal clot formation and supports healthier blood flow regulation. The medication targets the underlying enzyme deficiency associated with congenital TTP and may help reduce the risk of acute disease episodes and complications.
Adzynma is a recombinant enzyme replacement therapy produced using recombinant DNA technology and was the first FDA-approved recombinant ADAMTS13 therapy specifically approved for congenital TTP treatment.
What Conditions Does Adzynma Treat?
Adzynma is FDA-approved for the treatment of congenital thrombotic thrombocytopenic purpura, also called congenital TTP or cTTP, in adults and children. The medication may be used both for prophylactic treatment to help prevent acute cTTP episodes and for on-demand treatment during active disease events.
Congenital TTP is a rare inherited blood disorder caused by very low or absent ADAMTS13 enzyme activity. Without enough functioning ADAMTS13 enzyme, abnormal clot formation may occur in small blood vessels throughout the body, potentially leading to serious complications involving the brain, kidneys, heart, and other organs.
Patients with cTTP may experience symptoms such as fatigue, bruising, neurologic symptoms, low platelet counts, anemia, abdominal pain, and organ-related complications during acute disease episodes. Ongoing preventive treatment and careful disease monitoring are often important parts of long-term management.
Because cTTP is a rare and complex condition, many patients receive ongoing care through specialized hematology centers experienced in rare blood disorders and infusion therapy management.
Benefits of Treatment
Adzynma may help reduce abnormal blood clot formation and lower the risk of acute cTTP episodes in patients with congenital thrombotic thrombocytopenic purpura. By replacing deficient ADAMTS13 enzyme activity, the medication addresses the underlying cause of the disorder rather than only managing symptoms.
Preventive treatment may help reduce hospitalizations, emergency interventions, and complications associated with microvascular clot formation. Improved disease management may also help reduce the risk of organ damage related to recurrent clotting episodes.
Because Adzynma was specifically developed as a recombinant ADAMTS13 enzyme replacement therapy for congenital TTP, the medication represents an important advancement in targeted rare disease treatment. Treatment schedules may vary depending on disease severity, clinical response, and healthcare provider recommendations.
Important Safety Information and Side Effects
Adzynma may cause serious allergic reactions, including anaphylaxis. Patients should seek immediate medical attention if they experience symptoms such as wheezing, chest tightness, difficulty breathing, rash, swelling, dizziness, or low blood pressure during or after infusion.
Some patients may develop neutralizing antibodies against ADAMTS13, which may reduce treatment effectiveness over time. Ongoing laboratory monitoring may be required to evaluate ADAMTS13 activity levels and monitor for antibody formation during treatment.
Patients receiving Adzynma should also be monitored for hypersensitivity reactions and potential immune responses related to host cell proteins used during medication production. Individuals with a history of allergic reactions to biologic therapies should discuss treatment risks and safety considerations with their healthcare provider before beginning therapy.
Common side effects may include:
- Headache
- Diarrhea
- Migraine
- Abdominal pain
- Nausea
- Upper respiratory tract infection
- Dizziness
- Vomiting
Infusion-related reactions may also occur in some patients during treatment.
Because congenital TTP is a rare and potentially serious blood disorder, patients often require ongoing monitoring and care through specialized hematology treatment centers. Individuals should always speak with their healthcare provider regarding the risks, benefits, and safety considerations associated with Adzynma treatment.
Access to Multiple Medications
Those looking for access to affordable Adzynma may also be looking for other affordable medications.
Here at Prescription Hope, we help patients get access to multiple medications every single day. This means that whether you qualify for one or many, we can offer you the same great service, no matter the number of meds you qualify for.
For every medication, it’s a simple $70.00 per month.
Why Choose Prescription Hope for Adzynma Assistance
Experienced Advocacy Support
For 20 years, we’ve helped patients across America with our expert advocacy service.
Ongoing Medication Management
We don’t stop at an approval. We continue to advocate for you as long as you are a patient with us.
Transparent Monthly Pricing
[Price-point] per med, per month. No gimmicks, hidden fees, or tricks.
Nationwide Medication Access Support
20 years. Hundreds of pharmaceutical manufacturers. Tens of thousands of healthcare providers. Our network spans the entire nation.
So if you’re looking for access to affordable Adzynma through the Adzynma Patient Assistance Program, then be sure to fill out our enrollment form today!
